[Brokerage Focus] Industrial Securities maintains WUXI XDC (02268) 'Shareholding' rating, expects the company's long-term growth rate to exceed the growth rate of the ADC Industry.

Jinwu Financial News | According to a research report from Industrial Securities, WUXI XDC (02268) is expected to achieve year-on-year revenue, net profit, and adjusted net profit growth of over 85%, 260%, and 170% respectively in 2024. The performance growth is mainly due to: 1. The continuous strong development of the downstream ADC and other bioconjugate drug industries; 2. The company has a leading position and competitive advantage as a global leader in ADC outsourcing; 3. Production facilities maintain high capacity utilization, and new capacities are being added successively, with stable operational efficiency growth, leading to continuous improvement in the company's profit margins. The report indicates that the company's Wuxi base covers the four core production lines for ADCs.

Jingwu Financial News02:15 ET

Express News | Morgan Stanley's Long Position in WuXi XDC Cayman Decreases to 1.97% on Jan 15 From 5.63% - HKEX

ReutersJan 20 04:09 ET

Hong Kong stock movement | WUXI XDC (02268) gained over 5% as the ADC Industry rapidly expands its demand. The company's revenue growth in 2024 is significantly higher than the guidance provided at the beginning of the year.

WUXI XDC (02268) rose over 5%, as of the time of writing, it increased by 5.21% to 30.3 Hong Kong dollars, with a trading volume of 59.955 million Hong Kong dollars.

Zhitong FinanceJan 19 20:59 ET

Morgan Stanley maintains WUXI XDC's Shareholding rating with a Target Price of 34.8 Hong Kong dollars.

Morgan Stanley released a research report stating that it maintains the "Shareholding" rating for WUXI XDC (02268) with a Target Price of 34.8 Hong Kong dollars. The company has announced strong performance for 2024 in advance and has also provided guidance for at least 35% performance growth by 2025, expressing confidence in achieving a compound annual growth rate of about 31% from 2024 to 2030, which is above the Industry average. The bank noted that WUXI XDC will launch the DP3 factory in mid-2025 and begin production in Singapore by the end of 2025, preparing for Global commercial projects. Morgan Stanley believes that the positive guidance for 2025 and robust long-term goals further highlight the group's rapid growth.

新浪港股Jan 17 01:26 ET

CICC: Maintain WUXI XDC (02268) "Outperform Industry" rating and raise the Target Price to HK$39.

CICC raised WUXI XDC's adjusted Net income for 2024/2025 by 58.9%/31.6% to 1.12 billion yuan/1.48 billion yuan.

Zhitong FinanceJan 16 20:15 ET

WuXi XDC Cayman Anticipates 260% Surge in Net Profit for 2024

MT NewswiresJan 15 02:01 ET